NIKKEI 225
38,710.04 +473.97 (+1.24%) HANG SENG
18,440.12 -138.18 (-0.74%) CRUDE OIL
78.62 +0.14 (+0.18%) GOLD FUTURES
2,330.80 -0.40 (-0.02%) DOW
38,852.27 +176.59 (+0.46%) Bitcoin GBP
50,530.42 -662.15 (-1.29%)
MorphoSys AG (MOR2.F)
| Previous close | 16.20 |
| Open | 16.20 |
| Bid | 16.50 x 0 |
| Ask | 16.80 x 0 |
| Day's range | 16.20 - 16.20 |
| 52-week range | 3.56 - 17.40 |
| Volume | |
| Avg. volume | 47 |
| Market cap | 2.523B |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Business Wire
MorphoSys AG Reports First Quarter 2024 Financial Results
PLANEGG/MUNICH, Germany, April 29, 2024--MorphoSys AG (FSE: MOR; NASDAQ: MOR) reports results for the first quarter of 2024.
- Business Wire
MorphoSys’ Management Board and Supervisory Board Recommend Shareholders Accept Public Takeover Offer by Novartis
PLANEGG/MUNICH, Germany, April 11, 2024--The Management Board and Supervisory Board of MorphoSys AG (FSE: MOR; NASDAQ: MOR) today issued a joint reasoned statement on the voluntary public takeover offer by Novartis BidCo AG, a wholly owned indirect subsidiary of Novartis AG (hereinafter collectively referred to as "Novartis"), recommending that shareholders accept the offer and tender their MorphoSys shares. Novartis offers MorphoSys shareholders € 68.00 per share in cash, representing a total e
- Business Wire
MorphoSys AG Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
PLANEGG/MUNICH, Germany, March 13, 2024--MorphoSys AG (FSE: MOR; NASDAQ: MOR) reports results for the fourth quarter and the full year 2023.
